Literature DB >> 17071125

Maculoplasty for age-related macular degeneration: reengineering Bruch's membrane and the human macula.

Lucian V Del Priore1, Tongalp H Tezel, Henry J Kaplan.   

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in the western world. Over the last decade, there have been significant advances in the management of exudative AMD with the introduction of anti-VEGF drugs; however, many patients with exudative AMD continue to lose vision and there are no effective treatments for advanced exudative AMD or geographic atrophy. Initial attempts at macular reconstruction using cellular transplantation have not been effective in reversing vision loss. Herein we discuss the current status of surgical attempts to reconstruct damaged subretinal anatomy in advanced AMD. We reinforce the concept of maculoplasty for advanced AMD, which is defined as reconstruction of macular anatomy in patients with advanced vision loss. Successful maculoplasty is a three-step process that includes replacing or repairing damaged cells (using transplantation, translocation or stimulation of autologous cell proliferation); immune suppression (if allografts are used to replace damaged cells); and reconstruction or replacement of Bruch's membrane (to restore the integrity of the substrate for proper cell attachment). In the current article we will review the rationale for maculoplasty in advanced AMD, and discuss the results of initial clinical attempts at macular reconstruction. We will then discuss the role of Bruch's membrane damage in limiting transplant survival and visual recovery, and discuss the effects of age-related changes within human Bruch's membrane on the initial attachment and subsequent proliferation of transplanted cells. We will discuss attempts to repair Bruch's membrane by coating with extracellular matrix ligands, anatomic reconstitution of the inner collagen layer, and the effects of Bruch's membrane reconstruction of ultrastuctural anatomy and subsequent cell behavior. Lastly, we will emphasize the importance of continued efforts required for successful maculoplasty.

Entities:  

Mesh:

Year:  2006        PMID: 17071125     DOI: 10.1016/j.preteyeres.2006.08.001

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  15 in total

1.  Enhancing RPE Cell-Based Therapy Outcomes for AMD: The Role of Bruch's Membrane.

Authors:  Janosch P Heller; Keith R Martin
Journal:  Transl Vis Sci Technol       Date:  2014-07-03       Impact factor: 3.283

2.  Relationship of stokes radius to the rate of diffusion across Bruch's membrane.

Authors:  Astrid Zayas-Santiago; Alan D Marmorstein; Lihua Y Marmorstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-01       Impact factor: 4.799

3.  Transplantation of reprogrammed embryonic stem cells improves visual function in a mouse model for retinitis pigmentosa.

Authors:  Nan-Kai Wang; Joaquin Tosi; Jennifer Mie Kasanuki; Chai Lin Chou; Jian Kong; Nancy Parmalee; Katherine J Wert; Rando Allikmets; Chi-Chun Lai; Chung-Liang Chien; Takayuki Nagasaki; Chyuan-Sheng Lin; Stephen H Tsang
Journal:  Transplantation       Date:  2010-04-27       Impact factor: 4.939

Review 4.  Ophthalmologic stem cell transplantation therapies.

Authors:  Timothy A Blenkinsop; Barbara Corneo; Sally Temple; Jeffrey H Stern
Journal:  Regen Med       Date:  2012-11       Impact factor: 3.806

5.  Reengineering Human Bruch's Membrane Increases Rod Outer Segment Phagocytosis by Human Retinal Pigment Epithelium.

Authors:  Ernesto F Moreira; Hui Cai; Tongalp H Tezel; Mark A Fields; Lucian V Del Priore
Journal:  Transl Vis Sci Technol       Date:  2015-10-30       Impact factor: 3.283

6.  Transplantation of amniotic membrane to the subretinal space in pigs.

Authors:  Jens Folke Kiilgaard; Erik Scherfig; Jan Ulrik Prause; Morten la Cour
Journal:  Stem Cells Int       Date:  2012-03-05       Impact factor: 5.443

7.  Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration.

Authors:  Heather Melville; Matthew Carpiniello; Kia Hollis; Andrew Staffaroni; Nady Golestaneh
Journal:  J Transl Med       Date:  2013-03-01       Impact factor: 5.531

Review 8.  Genetic basis of inherited macular dystrophies and implications for stem cell therapy.

Authors:  Carla B Mellough; David H W Steel; Majlinda Lako
Journal:  Stem Cells       Date:  2009-11       Impact factor: 6.277

Review 9.  Vascular endothelial growth factor (VEGF) in autoimmune diseases.

Authors:  Jozélio Freire Carvalho; Miri Blank; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2007-03-06       Impact factor: 8.542

Review 10.  Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid.

Authors:  Francesco Morescalchi; Sarah Duse; Elena Gambicorti; Mario R Romano; Ciro Costagliola; Francesco Semeraro
Journal:  Mediators Inflamm       Date:  2013-09-30       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.